Russia's Rusnano supports HSCI/Pharmsynthez's $100 million new drugs development project
This article was originally published in Scrip
A project proposed by Moscow-based company HSCI (Human Stem Cells Institute), in which St Petersburg-based Pharmsynthez will also take part, will receive financial support from Russia's state corporation of nanotechnologies, Rusnano. Pharmsynthez estimated that the project would cost Rb3 billion ($100 million).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.